A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

CardioFocus Reports 10,000+ Patients Worldwide Have Been Treated with the HeartLight® Endoscopic Ablation System

December 15, 2020

CardioFocus HeartLight System is a revolutionary catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for AFib. HeartLight is a treatment option for some patients whose AFib is insufficiently controlled with medication1.

CardioFocus is celebrating the treatment of the 10,000th patient by thanking the countless researchers, scientists, clinicians, suppliers, vendors, partners, investors, and employees (both past and present) that helped develop the HeartLight System.

Extensive clinical studies of the HeartLight System and the new HeartLight X3 System demonstrated that AFib patients can be treated quickly and with excellent procedure time predictability.2 In May of this year, the U.S. Food and Drug Administration (FDA) approved the next-generation HeartLight X3 System. This third-generation HeartLight X3 System offers a unique RAPID mode, which includes precise motor control that enables uninterrupted, high-speed, circumferential lesion creation under direct visual control of the physician resulting in consistently reduced procedure times.3

“As an early adopter of the HeartLight System, I have seen firsthand the benefits this transformational technology provides AFib patients,” said Henry D. Huang, M.D., a cardiac electrophysiologist at Rush University Medical Center in Chicago. “The speed, control, predictability, and durability of HeartLight X3 are unparalleled and allow us to customize the treatment based on the unique needs of each patient.”

More than 33 million patients worldwide suffer from AFib,4 which has been associated with significant symptoms, functional impairment, stroke, cognitive decline, heart failure, and reduced longevity.

“We are committed to providing our AFib patients with the latest advancements in cardiac treatments, including devices like the HeartLight X3 System,” said David N. Kenigsberg, MD, a clinical cardiac electrophysiologist and medical director of the electrophysiology laboratory at Westside Regional Medical Center in Plantation, Fla. “I am honored to be among the group of electrophysiologists helping to achieve the 10,000 patient HeartLight milestone and furthering the reach of this revolutionary technology.”

“CardioFocus values our partners and the leaders in the electrophysiology community who have made this noteworthy milestone a reality. Their collaboration and unwavering commitment to exceptional patient care have expedited the adoption of this technology at a remarkable pace,” said Burke T. Barrett, Chief Executive Officer & President at CardioFocus. “With more than 10,000 patients treated worldwide, we believe this is only the beginning, as CardioFocus is positioned to become a dominant force in the rapidly growing AFib ablation market with our proven HeartLight X3 System.”


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy